A carregar...
The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal
BACKGROUND: Erenumab, a fully human monoclonal antibody directed against the calcitonin gene-related peptide receptor, was approved for the prevention of episodic (EM) or chronic migraine (CM) at the monthly dose of 70 mg or 140 mg. We reviewed the available literature to understand if patients with...
Na minha lista:
| Publicado no: | J Headache Pain |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer Milan
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6822439/ https://ncbi.nlm.nih.gov/pubmed/31666008 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s10194-019-1054-4 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|